KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Other Working Capital Changes (2017 - 2025)

Aquestive Therapeutics has reported Other Working Capital Changes over the past 9 years, most recently at -$399000.0 for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$399000.0 for Q4 2025, down 130.55% from a year ago — trailing twelve months through Dec 2025 was -$1.7 million (down 840.81% YoY), and the annual figure for FY2025 was -$698000.0, down 413.0%.
  • Other Working Capital Changes for Q4 2025 was -$399000.0 at Aquestive Therapeutics, up from -$1.2 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for AQST hit a ceiling of $4.0 million in Q2 2023 and a floor of -$5.4 million in Q3 2023.
  • Median Other Working Capital Changes over the past 5 years was $241500.0 (2022), compared with a mean of -$268800.0.
  • Biggest five-year swings in Other Working Capital Changes: tumbled 1711.64% in 2023 and later soared 1889.04% in 2024.
  • Aquestive Therapeutics' Other Working Capital Changes stood at $535000.0 in 2021, then surged by 33.08% to $712000.0 in 2022, then plummeted by 110.25% to -$73000.0 in 2023, then soared by 1889.04% to $1.3 million in 2024, then plummeted by 130.55% to -$399000.0 in 2025.
  • The last three reported values for Other Working Capital Changes were -$399000.0 (Q4 2025), -$1.2 million (Q3 2025), and $397000.0 (Q2 2025) per Business Quant data.